A number of HER2-ADC products have been granted approval, with Kadcyla (trastuzumab emtansine) and Enhertu (trastuzumab deruxtecan) approved for the treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.